Bayer aims to make healthcare breakthrough innovation

23-Jan-2021 Intellasia | The Saigon Times | 6:02 AM Print This Post

Bayer on January 13 hosted Virtual Pharma Media Day to present its progress in transforming its pharmaceutical business with breakthrough innovation in healthcare.

Under theme “Transforming Healthcare. Transforming Bayer,” the online event focused on strategic ambition of Bayer in the areas of cell and gene therapy, digital health and by driving forward the company’s promising development portfolio.

The cell and gene therapies are expected to shift the paradigm of disease treatment to cure. Bayer has established a new Cell and Gene Therapy Platform which steers the company’s strategy in the area and orchestrates all activities along the value chain providing an innovation ecosystem for all partners, including two subsidiaries of Bayer: Blue Rock Therapeutics and Asklepios BioPharmaceutical.

Wolfram Carius, a speaker at the event as well as executive VP and head of Cell and Gene Therapy at Bayer, said in the cell and gene therapies, moving from treating symptoms to curative approaches is a way that is believed to impact patients’ lives.

Digital healthcare was also a key topic mentioned at the online event. Digital health is emerging as a vital pillar of modern healthcare. Integrated care is an application of digital health aiming to develop coordinated concepts of care, supporting patients throughout their lives, accounting for multi-morbidity and offering the support they need. Jeanne Kehren, senior VP of digital and commercial innovation of member of the Pharmaceuticals Executive Committee of Bayer AG, said at the event that by focusing on the individual patient, not their disease, the integrated care is the path to inclusive and personalised healthcare.

At the event, experts from Bayer also introduced two pipeline programmes in mid-stage development demonstrating medical innovation at the company, which are Factor XI-targeting compound programme and P2X3 multi-indication programme.

According to So-Young Kim, MD, head of Thrombosis and Vascular Diseases at Bayer, Factor XI (FXI) is a naturally occurring enzyme that is part of the coagulation cascade which plays a key role in the formation of pathological blood clots and consequently thrombosis.

Bayer is advancing a mid-stage programme of FXI-targeting compounds, a new class of anticoagulants. FXI-pathway inhibition may offer protection from thromboembolic events without increased risk of bleeding.

Given P2X3 multi-indication programme, Oliver Martin Fischer, principal scientist for reproductive health at Bayer, said P2X3 is a protein which is mainly expressed on sensory nerve fibers. At Bayer, the promise of P2X3 antagonists was first identified for endometriosis within the company’s strategic research alliance with Evotec, a Germany-based drug discovery and development company.


Category: Business, Vietnam

Print This Post

Leave a Reply

You must be logged in to post a comment.